Natixis Advisors, L.P. Roivant Sciences Ltd. Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 153,717 shares of ROIV stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
153,717
Previous 141,991
8.26%
Holding current value
$1.67 Million
Previous $1.5 Million
18.27%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ROIV
# of Institutions
317Shares Held
507MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$718 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$716 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$589 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$454 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$385 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.67B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...